These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 28903120)

  • 21. Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial.
    Amminger GP; Schäfer MR; Papageorgiou K; Klier CM; Cotton SM; Harrigan SM; Mackinnon A; McGorry PD; Berger GE
    Arch Gen Psychiatry; 2010 Feb; 67(2):146-54. PubMed ID: 20124114
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of omega-3 fatty acids for indicated prevention of young patients at risk for psychosis: when do they begin to be effective?
    Mossaheb N; Schäfer MR; Schlögelhofer M; Klier CM; Cotton SM; McGorry PD; Amminger GP
    Schizophr Res; 2013 Aug; 148(1-3):163-7. PubMed ID: 23778032
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Baseline differences in clinical symptomatology between ultra high risk subjects with and without a transition to psychosis.
    Velthorst E; Nieman DH; Becker HE; van de Fliert R; Dingemans PM; Klaassen R; de Haan L; van Amelsvoort T; Linszen DH
    Schizophr Res; 2009 Apr; 109(1-3):60-5. PubMed ID: 19272756
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cannabis-induced attenuated psychotic symptoms: implications for prognosis in young people at ultra-high risk for psychosis.
    McHugh MJ; McGorry PD; Yung AR; Lin A; Wood SJ; Hartmann JA; Nelson B
    Psychol Med; 2017 Mar; 47(4):616-626. PubMed ID: 27821204
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Randomized controlled trial of interventions for young people at ultra-high risk of psychosis: study design and baseline characteristics.
    Phillips LJ; Nelson B; Yuen HP; Francey SM; Simmons M; Stanford C; Ross M; Kelly D; Baker K; Conus P; Amminger P; Trumpler F; Yun Y; Lim M; McNab C; Yung AR; McGorry PD
    Aust N Z J Psychiatry; 2009 Sep; 43(9):818-29. PubMed ID: 19670055
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cognitive therapy for the prevention of psychosis in people at ultra-high risk: randomised controlled trial.
    Morrison AP; French P; Walford L; Lewis SW; Kilcommons A; Green J; Parker S; Bentall RP
    Br J Psychiatry; 2004 Oct; 185():291-7. PubMed ID: 15458988
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Relationship between membrane fatty acids and cognitive symptoms and information processing in individuals at ultra-high risk for psychosis.
    Kim SW; Schäfer MR; Klier CM; Berk M; Rice S; Allott K; Bartholomeusz CF; Whittle SL; Pilioussis E; Pantelis C; McGorry PD; Amminger GP
    Schizophr Res; 2014 Sep; 158(1-3):39-44. PubMed ID: 25066495
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predictors of treatment response in young people at ultra-high risk for psychosis who received long-chain omega-3 fatty acids.
    Amminger GP; Mechelli A; Rice S; Kim SW; Klier CM; McNamara RK; Berk M; McGorry PD; Schäfer MR
    Transl Psychiatry; 2015 Jan; 5(1):e495. PubMed ID: 25585167
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relationship between allostatic load and clinical outcomes in youth at ultra-high risk for psychosis in the NEURAPRO study.
    Berger M; Lavoie S; McGorry PD; Nelson B; Markulev C; Yuen HP; Schaefer M; Sarnyai Z; Amminger GP
    Schizophr Res; 2020 Dec; 226():38-43. PubMed ID: 30340917
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Attenuated psychosis syndrome: A new diagnostic category for further study in DSM-5].
    Samiotakis G; Kollias C; Lazaratou H; Anagnostopoulos D; Kontaxakis V
    Psychiatriki; 2017; 28(2):120-130. PubMed ID: 28686559
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Attenuated psychotic symptom interventions in youth at risk of psychosis: A systematic review and meta-analysis.
    Devoe DJ; Farris MS; Townes P; Addington J
    Early Interv Psychiatry; 2019 Feb; 13(1):3-17. PubMed ID: 29749710
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The FOCUS trial: cognitive remediation plus standard treatment versus standard treatment for patients at ultra-high risk for psychosis: study protocol for a randomised controlled trial.
    Glenthøj LB; Fagerlund B; Randers L; Hjorthøj CR; Wenneberg C; Krakauer K; Vosgerau A; Gluud C; Medalia A; Roberts DL; Nordentoft M
    Trials; 2015 Jan; 16():25. PubMed ID: 25623736
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Improving the clinical prediction of psychosis by combining ultra-high risk criteria and cognitive basic symptoms.
    Schultze-Lutter F; Klosterkötter J; Ruhrmann S
    Schizophr Res; 2014 Apr; 154(1-3):100-6. PubMed ID: 24613572
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antidepressant, antipsychotic and psychological interventions in subjects at high clinical risk for psychosis: OASIS 6-year naturalistic study.
    Fusar-Poli P; Frascarelli M; Valmaggia L; Byrne M; Stahl D; Rocchetti M; Codjoe L; Weinberg L; Tognin S; Xenaki L; McGuire P
    Psychol Med; 2015 Apr; 45(6):1327-39. PubMed ID: 25335776
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of cognitive therapy on the longitudinal development of psychotic experiences in people at high risk of developing psychosis.
    French P; Shryane N; Bentall RP; Lewis SW; Morrison AP
    Br J Psychiatry Suppl; 2007 Dec; 51():s82-7. PubMed ID: 18055943
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predictors of longer-term outcome in the Vienna omega-3 high-risk study.
    Mossaheb N; Schäfer MR; Schlögelhofer M; Klier CM; Smesny S; McGorry PD; Berger M; Amminger GP
    Schizophr Res; 2018 Mar; 193():168-172. PubMed ID: 28823721
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cognitive Behavioral Therapy for Psychosis (CBT-p) Delivered in a Community Mental Health Setting: A Case Comparison of Clients Receiving CBT Informed Strategies by Case Managers Prior to Therapy.
    Sivec HJ; Montesano VL; Skubby D; Knepp KA; Munetz MR
    Community Ment Health J; 2017 Feb; 53(2):134-142. PubMed ID: 26298476
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Indicated prevention with long-chain polyunsaturated omega-3 fatty acids in patients with 22q11DS genetically at high risk for psychosis. Protocol of a randomized, double-blind, placebo-controlled treatment trial.
    Armando M; De Crescenzo F; Vicari S; Digilio MC; Pontillo M; Papaleo F; Amminger GP
    Early Interv Psychiatry; 2016 Oct; 10(5):390-6. PubMed ID: 25345540
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adolescents at ultra-high risk for psychosis: long-term outcome of individuals who recover from their at-risk state.
    de Wit S; Schothorst PF; Oranje B; Ziermans TB; Durston S; Kahn RS
    Eur Neuropsychopharmacol; 2014 Jun; 24(6):865-73. PubMed ID: 24636460
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Symptomatology and neuropsychological functioning in cannabis using subjects at ultra-high risk for developing psychosis and healthy controls.
    Korver N; Nieman DH; Becker HE; van de Fliert JR; Dingemans PH; de Haan L; Spiering M; Schmitz N; Linszen DH
    Aust N Z J Psychiatry; 2010 Mar; 44(3):230-6. PubMed ID: 20180725
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.